 "Ipca Labs nears 52-week low on USFDA bans import of drugs from three plants")
Ipca Laboratories tanked 15% to Rs 437 on BSE in intra-day trade after the company said the US Food and Drugs Administration (USFDA) has refused admission to all drugs made at the company's Pithampur and Silvassa facility. The stock is currently trading near to its 52-week low of Rs 435 touched on June 24, 2016.
“The ban on all drugs made at Pithampur (Madhya Pradesh) and Silvassa (Dadra and Nagar Haveli) will continue "until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with the current good manufacturing practice regulation (CGMP) ," Ipca Laboratories said in a statement.
The USFDA cited violation of current good manufacturing norms for taking the step against the company.
All drugs except API Chloroquine Phosphate made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US, it further said.
However, it said the US health regulator will reconsider the exception for Chloroquine Phosphate made at the Ratlam facility, if shortage and/or medical necessity implications change.
At 9:53 am; the stock was trading 7% lower at Rs 479 on BSE as compared to 0.09% rise in the S&P BSE Sensex. The trading volumes on the counter jumped multiple-fold with a combined 3.83 million shares changed hands on the BSE and NSE so far.
“The ban on all drugs made at Pithampur (Madhya Pradesh) and Silvassa (Dadra and Nagar Haveli) will continue "until the company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with the current good manufacturing practice regulation (CGMP) ," Ipca Laboratories said in a statement.
The USFDA cited violation of current good manufacturing norms for taking the step against the company.
All drugs except API Chloroquine Phosphate made at Ratlam (Madhya Pradesh) unit have also been denied entry in the US, it further said.
However, it said the US health regulator will reconsider the exception for Chloroquine Phosphate made at the Ratlam facility, if shortage and/or medical necessity implications change.
At 9:53 am; the stock was trading 7% lower at Rs 479 on BSE as compared to 0.09% rise in the S&P BSE Sensex. The trading volumes on the counter jumped multiple-fold with a combined 3.83 million shares changed hands on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%